KTTA
Pasithea Therapeutics Corp. Common Stock
Latest price
As of Oct 28, 2026, 4:41 PM EDT · Market data by Massive
Market cap
$13.3M
Volume
596.8K
Previous close
$0.3973
Day range
$0.3686 – $0.4000
Listed
Sep 15, 2021
Coverage
11 articles
Price performance
Recent trading
Newsroom
Latest KTTA coverage
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAMPAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity GlialCAM fragment is present in MonkeyPox virus, supporting a potential role in current vaccine development Miami Beach, FL / August 11, 2022 — Pasithea Therapeutics Corp. (
Pasithea Therapeutics Awarded a Drug Development Research Grant
AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction Provides approximately U.S. $694,000 of non-dilutive funding MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company f
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
Alpha-5 is a potentially First-In-Class monoclonal antibody for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurological diseasesExpands pipeline across Pasithea's core therapeutic areas to drive enhanced growthClosing consideration of 3.26 million shares of Pasithea common stockPasithea to hold a webcast on June 22 at 9 a.m. ET to discuss
Pasithea Therapeutics Announces Collaboration with The Glimpse Group
The Glimpse Group is a Virtual Reality and Augmented Reality platform companyPartnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders Miami Beach, FL / March 8, 2022 — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis
Company commences program to develop a tolerizing vaccine and names Hooke Laboratories as its research partner Miami Beach, FL / February 3, 2022 — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disor
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
Expanding Pasithea Clinics footprint in London Miami Beach, FL / December 21, 2021 — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, P
Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada
Miami Beach, FL / December 1, 2021 — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Pasithea Clinics, its wholly owned subsidiary, has expanded the availability o
Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
Pasithea Clinics to offer ketamine infusion therapy for the treatment of mental health disordersFirst mobile clinics launch in New York City, Los Angeles, San Diego, and San Francisco, with expansion to additional U.S. cities in coming monthsTreatments conducted by board-certified medical professionals Miami Beach, FL / November 17, 2021 — Pasithea The
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders Miami Beach, FL / October 27, 2021 — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric
Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom
Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disordersKetamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric disorders, such as treatment resistant depression and post-traumatic stress disorder Miami
Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement
Miami Beach, FL / October 11, 2021 — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the initiation of a new chemical entity (“NCE”) development program and named Evotec as i